A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Prior treatment

• Has had an allogeneic tissue/solid organ transplant in the last 5 years

Other illness

• If HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• Has known additional malignancy that is progressing or has required active treatment within the past 2 years
• Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy
• Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids
• Has current pneumonitis/interstitial lung disease
• Has active infection requiring systemic therapy
• Has known history of Hepatitis B (defined as Hepatitis B surface antigen reactive) or known active Hepatitis C virus infection

Other

• The key exclusion criteria include but are not limited to the following:
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

• The key inclusion criteria include but are not limited to the following:
• Has histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report who have experienced disease progression on or after prior anti-cancer treatments, or been intolerant to, or refused all treatment known to confer clinical benefit
• Has head and neck squamous cell carcinoma (HNSCC), melanoma (cutaneous), non-small cell lung cancer (NSCLC), cervical cancer, triple negative breast cancer (TNBC), urothelial carcinoma (UC), or renal cell carcinoma (RCC; clear cell, papillary)
• If human immunodeficiency virus (HIV) infected, must have well controlled HIV on antiretroviral therapy (ART)
• Has normal cardiac function